Clinical trials
Completed trials in Hong Kong
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
2,351 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 12 |
| 2002 | 15 |
| 2003 | 27 |
| 2004 | 32 |
| 2005 | 54 |
| 2006 | 70 |
| 2007 | 73 |
| 2008 | 77 |
| 2009 | 91 |
| 2010 | 101 |
| 2011 | 74 |
| 2012 | 83 |
| 2013 | 88 |
| 2014 | 100 |
| 2015 | 117 |
| 2016 | 107 |
| 2017 | 152 |
| 2018 | 170 |
| 2019 | 151 |
| 2020 | 164 |
| 2021 | 169 |
| 2022 | 159 |
| 2023 | 128 |
| 2024 | 88 |
| 2025 | 33 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 2,351 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The University of Hong Kong | 435 |
| Chinese University of Hong Kong | 424 |
| The Hong Kong Polytechnic University | 233 |
| Hoffmann-La Roche | 102 |
| Novartis Pharmaceuticals | 88 |
| GlaxoSmithKline | 64 |
| Bayer | 51 |
| Pfizer | 48 |
| AstraZeneca | 44 |
| Boehringer Ingelheim | 43 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 77 |
| Stroke | 76 |
| Diabetes Mellitus, Type 2 | 75 |
| Carcinoma, Hepatocellular | 71 |
| Breast Neoplasms | 68 |
| Neoplasms | 58 |
| Diabetes Mellitus | 54 |
| Hepatitis B, Chronic | 53 |
| Sleep Initiation and Maintenance Disorders | 38 |
| Hepatitis B | 35 |
Trials
Showing 1 to 25 of 2,351. Each trial links to its page on Pharma Observatory.
2,251 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.